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ABSTRACT
Worldwide, millions of patients are affected annually by healthcare-associated infection (HCAI),
impacting up to 80,000 patients in European Hospitals on any given day. This represents not only
public health risk, but also an economic burden.
Complementing routine hand hygiene practices, cleaning and disinfection, antimicrobial coatings
hold promise based, in essence, on the application of materials and chemicals with persistent
bactericidal or –static properties onto surfaces or in textiles used in healthcare environments.
The focus of considerable commercial investment and academic research energies, such
antimicrobial coating-based approaches are widely believed to have potential in reduction of
microbial numbers on surfaces in clinical settings. This belief exists despite deﬁnitive evidence as to
their efﬁcacy and is based somewhat on positive studies involving, for example, copper, silver or
gold ions, titanium or organosilane, albeit under laboratory conditions. The literature describes
successful delay and/or prevention of recontamination following conventional cleaning and
disinfection by problematic microbes such as methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin resistant enterococci (VRE), among others. However, there is a scarcity of studies
assessing antimicrobial surfaces other than copper in the clinical environment, and a complete lack
of published data regarding the successful implementation of these materials on clinically
signiﬁcant outcomes (including HCAI).
Through its Cooperation in Science and Technology program (COST), the European Commission
has funded a 4-year initiative to establish a network of stakeholders involved in development,
regulation and use of novel anti-microbial coatings for prevention of HCAI. The network (AMiCI)
comprises participants of more than 60 universities, research institutes and companies across 29
European countries and, to-date, represents the most comprehensive consortium targeting use of
these emergent technologies in healthcare settings.
More speciﬁcally, the network will prioritise coordinated research on the effects (both positive
and negative) of antimicrobial coatings in healthcare sectors; know-how regarding availability and
mechanisms of action of (nano)-coatings; possible adverse effects of such materials (e.g., potential
emergence of microbial resistance or emission of toxic agents into the environment); standardised
performance assessments for antimicrobial coatings; identiﬁcation and dissemination of best
practices by hospitals, other clinical facilities, regulators and manufacturers.
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Introduction
Healthcare-associated infections (HCAI), also termed
nosocomial infections, are complications of healthcare
that result in elevated patient morbidity and mortal-
ity.1 HCAI increase healthcare costs for patients, hos-
pitals and insurers due to extended hospitalization
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and associated care. There is also a psychological bur-
den placed on patients, their carers and families, in
addition to opportunity costs subsequent to patients’
and their carers’ inability to work, attend school, etc.,
while unanticipated reduction of hospital capacity
impacts the efﬁciency of healthcare.2,3 It has been esti-
mated that, in the US alone, HCAI affects approxi-
mately 2 million patients annually of whom
approximately 90,000 die. This is associated with an
annual cost estimated to range from US$ 28 billion to
45 billion.4 Similarly, in the European Union, the
European Center for Disease Prevention and Control
(ECDC) advises that approximately 4.1 million acute
care patients acquire a HCAI annually, with 37,000
deaths attributed directly to HCAI.5
There is a dichotomy in awareness of HCAI, with
much media and public focus on Gram-positive
Staphylococcus aureus-associated outbreaks, while the
reality is that Gram-negative species currently repre-
sent the greater risk. More speciﬁcally, monitoring of
outbreak incidence and individual cases has shown
that while, for instance, the prevalence of meticillin-
resistant Staphylococcus aureus (MRSA) is stabilizing
and even decreasing in some European countries,
other HCAI are increasing (e.g., Escherichia coli and
Klebsiella pneumoniae).5 Such monitoring, including
pan-European surveillance, has been expanded to
encompass long-term care facilities (LTCF) in addi-
tion to hospitals.6 Further to that, more comprehen-
sive data are emerging across Europe, such as in
Ireland where a recent national median HCAI preva-
lence of 4.2% in long-term care facilities was reported
albeit not consistently.7,8
Incidence of HCAI, however, are generally consid-
ered preventable.9 Although hand hygiene is widely
regarded as the most effective preventative measure
for health care workers, there is a recognized need for
novel methods in addition to appropriate cleaning,
use of disinfectants and antibiotics.10,11 One such
approach involves antimicrobial (nano)-coatings
(AMC),12 in which integrated active ingredients are
responsible for the elimination of microorganisms
that come into contact with treated surfaces. There
has been an emphasis on bactericidal applications for
use in healthcare settings, and a developing conﬁdence
in the potential for such coatings albeit based some-
what on studies involving, for example, silver or gold
ions, titanium or organosilane performed under labo-
ratory conditions.13 However, this conﬁdence is
bolstered by reports describing successful delay and/or
prevention of recontamination following conventional
cleaning and disinfection by problematic microbes
such as methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin resistant enterococci (VRE),
among others.14-17
More broadly, however, chemical strategies and tech-
nologies for antimicrobial coatings have been described
that utilize active eluting agents (e.g., ions or nanopar-
ticles of silver, copper, zinc, or antibiotics, chloride, phy-
tochemicals, iodine, ammonium etc.), immobilized
molecules that become active upon contact (e.g., quater-
nary ammonium polymers or peptides), or light-acti-
vated molecules (e.g., TiO2 or photosensitizers).
18-20 A
2016 comprehensive systematic review reported a pau-
city of studies evaluating non-copper antimicrobial sur-
faces in clinical environments, and a total lack of peer-
reviewed data relating to successful implementation of
materials other than copper on clinically relevant out-
comes (including HCAI).21 However, since that review
was written, Molling et al. have reported a dominance of
nanosilver in nanoparticle-based coatings, and associated
adequate in situ performance.13 Furthermore, copper
touch surfaces in Finnish facilities such as hospital
patient rooms and kindergartens lowered total bacterial
counts and reduced occurrence of Staphylococcus aureus
when compared with non-copper touch surfaces.22 The
application of copper and/or its alloys was also reported
to reduce bacterial numbers on often touched surfaces in
intensive care units.23 A positive effect of AMC on reduc-
tion of HAIs was also shown by von Dessauer et al.
whereby HAI rates of 10.6 versus 13.0 per 1,000 patient
days were observed for copper- and non-copper-
“exposed’ patients, respectively, albeit that the difference
was not statistically signiﬁcant.24 In an alternate
approach, recognizing that bacterial adhesion can be crit-
ical in successful host colonization or in the external
environment,25 the antimicrobial effects of coatings with
controlled nanotopography are being developed which
aim to repel bacterial adhesion based on physical
properties.26,27
But, prudence is needed. The introduction of
(nano)-coatings with novel active components (e.g.,
nanosilver), some of which many be affected by vary-
ing end-user cleaning methods, may cause emission of
bioactive agents into the environment and thereby
facilitate potential exposure of humans, livestock and
microorganisms to low concentrations of these. Indeed,
the biocidal products are intrinsically toxic, i.e.
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showharmful effects toward different types of cells/
organisms and, thus, not only affect the target organ-
isms (such as pathogenic bacteria) but can be harmful
also to humans and also to all types of environmental
organisms.28,29 As described in the One Health Initia-
tive (http://www.onehealthinitiative.com), these agents
(e.g., AgNP, AgC, CuNP, and TiO2) may have poten-
tial for impact on organisms living in water and soil
compartments, speciﬁcally. In addition, the slow infu-
sion of active ingredients may induce antimicrobial
resistances (AMR) that differ from antibiotic-driven
mechanisms.30 Indeed, several genes encoding enzyme
synthesis responsible for resistance to metallic and
other compounds used in AMCs have been identiﬁed
within hospital environments with some described as
plasmid-borne or readily transferable.31-34
The widespread introduction of such coatings
clearly needs to be subject to expert risk-beneﬁt analy-
ses and is subject to signiﬁcant scrutiny at the regula-
tory level; a lack of clear evidence of beneﬁts and a
poor understanding of risks may result in the loss of
potentially valuable intervention strategies remaining
available to the healthcare sector should such material
not be approved by regulatory bodies.
Cost actions
COST Actions are a ﬂexible, fast, effective and efﬁcient
networking instrument for researchers, engineers and
scholars to cooperate and coordinate nationally
funded research activities. COST Actions allow Euro-
pean researchers to jointly develop their own ideas in
any science and technology ﬁeld (http://www.cost.eu/
COST_Actions). More speciﬁcally, COST Actions are
bottom-up science and technology networks, open to
researchers and stakeholders with a duration of 4 y.
They utilize a range of networking tools, such as work-
shops, conferences, training schools, short-term scien-
tiﬁc missions (STSMs), and dissemination activities.
AMiCI cost action (CA15114)
The network (http://www.cost.eu/COST_Actions/
ca/CA15114) represents collaboration of stakeholders
from different countries and disciplines, including
third level institutes and universities, antimicrobial
coating producers and processors, and organizations
responsible for compliance with international stand-
ards. This network complements the closely related
COST Action iPROMEDAI (http://www.cost.eu/COS
T_Actions/tdp/TD1305) the activities of which con-
centrate on timed presentation and localized delivery
of antimicrobial compounds in medical devices, such
as catheters, to reduce the incidence of device-associ-
ated infections due to bioﬁlm formation.
AMiCI focuses speciﬁcally on generating new capa-
bilities related to:
 systematic, international coordinated research on
the effects (both positive and negative) of antimi-
crobial coatings in healthcare or other sectors;
 know-how regarding the availability and use of
different materials, mechanisms of action of
(nano)-coatings and the desired use in different
applications, procedures and products;
 information about the possible adverse effects of
such materials, e.g., the potential induction of
new resistance mechanisms in bacteria or emis-
sion of toxic agents into the environment;
 standard performance assessments for antimi-
crobial coatings, applicable in laboratory settings
and, thereby, direct comparison of different coat-
ings from different producers;
 standard performance assessments to determine
functionality of coatings in a(n) (extreme) test
condition, ﬁeld tests or benchmark methods to
assess the efﬁcacy in ﬁeld conditions;
 communication and/or publication of best prac-
tices by hospitals, other clinical facilities, regula-
tors or product suppliers;
 development of safe by design concepts allowing
the identiﬁcation of risks and uncertainties dur-
ing innovation projects and enabling their seam-
less integration into the innovation process. In
the context of AMCs, safe by design is intended
to include the active antimicrobial ingredient
(and other constituents of the coatings) whether
integrated into a ﬁnished coating product or
eluted from it such that its potential intended,
unintended and/or unforeseen effects can be
monitored, understood and mitigated, where
possible and appropriate.
In doing so, AMiCI recognizes the critical importance
of compliance with the European Biocidal Products Reg-
ulation (BPR, Regulation (EU) 528/2012), which con-
cerns the placing on the market and use of biocidal
products, which are used to protect humans, animals,
materials or articles against harmful organisms, like pests
or bacteria, by the action of the active substances con-
tained in the biocidal product (Fig. 1).
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The program
The AMiCI work has been designed to allow focus
across 4 y of planned activities on 5 speciﬁc, intercon-
nected themes.
Theme one: Antimicrobial materials that are safe by
design
When developing antimicrobial coatings, insight
regarding the site of use is crucial. The nature of the
surface (e.g., clothing, movable door components,
static surfaces, etc) must be considered. For example,
the same antimicrobial coating if applied inappropri-
ately of differing surfaces of differing characteristics
may lead to a release of biocides due to incomplete
chemical binding or the inﬂuence of UV radiation
that is required to activate the relevant bioactive anti-
microbial property. Therefore, this theme targets the
generation of enhanced understanding of antimicro-
bial mechanisms and how these may be impacted
through construction of physical infrastructure, appli-
cation to surfaces, production processes etc such that
available coatings can be adapted or new coatings
developed to meet European Biocidal Product require-
ments (BPR).
Theme two: Performance assessment (laboratory –
ﬁeld – benchmark)
Current and new AMCs will enter the European mar-
ket only if their efﬁcacy is proven in appropriate ﬁeld-
testing, and when they comply with the BPR. Testing
AMCs in a healthcare environment has ethical and
practical challenges, and it is expected that the site of
intervention (textiles, cleaning, surfaces) will have
considerable inﬂuence on the overall ecosystem of the
care environment. Therefore, it is important to
develop laboratory, ﬁeld and benchmark tests that can
help predict the effectiveness of coating components
as part of the cleaning processes used in healthcare. In
addition, it is necessary to predict the overall efﬁciency
of such interventions on bacterial contamination in
healthcare facilities. This is considered critical as,
although the efﬁcacy and efﬁciency may be predicted
and even demonstrated, the perceptions of healthcare
professionals may continue to favor disinfection
before adoption of new preventative technologies.
Further, it is anticipated that the continued imple-
mentation of the BPR (and other regulations else-
where in the world) will result in signiﬁcant reduction
of available coatings in the market (access to global
markets is often an important factor when a company
considers the development of new coatings and sys-
tems). This combination of events signals the reason-
ably urgent need for guidelines by which healthcare
facilities, as well as manufacturers, can produce and
assess antimicrobial products. Part of such guidelines
ought to be relatively simple, quick and reliable tests
that can evaluate such coatings, their application and
durability. AMiCI participants in this theme will work
toward the design of suitable tests.
Theme three: Adverse effects / risk – beneﬁt analyses
Introduction of antimicrobial (nano)coatings into
widespread use has the potential to cause emission
into the environment of bioactive components such as
nanosilver, copper and/or zinc. It is, therefore, essen-
tial that the impact, following exposure of these active
agents, on humans, livestock and other animals, and
microorganisms be assessed. Given the context of their
use, potential induction of antimicrobial resistance is
of particular importance. However, comprehensive
toxicological studies are also needed to allow risk -
beneﬁt analyses. AMiCI will attempt to generate the
analytical data required to advise regulatory agencies,
in addition to working with producers of antimicro-
bial coatings on the development of safe-by-design
products.
Theme four: The new cleaning
For decades, cleaning and hygiene practices in health-
care have been conservative, with little variation in
Figure 1. AMiCI will deliver insights into the impact of novel anti-
microbial coatings on healthcare acquired infections, the compo-
sition of those coatings, new cleaning processes, environmental
impact, and potential emergence of antimicrobial resistance.
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detergent and disinfectant technology or use. Innova-
tion is now required due to both organic pollution
risks and emergence of multidrug-resistant microbes.
The introduction of antimicrobial coatings may repre-
sent a step-change. However, along with these prod-
ucts will come new practices, new environmental
monitoring and training requirements. AMiCI will
compare efﬁcacy of cleaning practices in the context
of new coating technologies across varying sites, and
will generate guidelines appropriate for healthcare
facilities. In doing so, due consideration will be paid to
the fact that while evidence points to near patient sur-
faces having inadequate cleaning, mechanical cleaning
processes in addition to chemical interactions may
reduce the efﬁcacy of AMCs to sub-inhibitory levels
and result in generation of resistance, such as has been
demonstrated with liquid disinfectants.35,36 The possi-
bility of over-reliance on AMCs and the potential
compromising of adequate resourcing and appropriate
cleaning procedures will also be explored.
Theme ﬁve: Communication and dissemination
Antimicrobial coatings are a relatively new techno-
logical solution in the battle against healthcare
acquired infections. At present, potential users have
little knowledge of their advantages, and associated
challenges. AMiCI will coordinate communication
of credible information regarding these innovations
in understandable and accessible formats through
social media, websites, conferences, trade fairs,
patient and professional fora, and scientiﬁc publica-
tions. The information will be tailored to the per-
spectives of inventors and entrepreneurs; academic
researchers; manufacturers; distributors; commer-
cial, clinical, biocide and consumer affairs regula-
tors; medicines agencies; clinical microbiologists;
attending physicians; healthcare facility managers
and procurement ofﬁcers; environmental monitor-
ing specialists and environmental protection agen-
cies; hygiene companies; and, of course, patients
and their carers.
Conclusion
Antimicrobial coatings represent innovation in
response to an impending healthcare challenge that
is unprecedented. Antimicrobial drugs of last resort
are beginning to fail, and outbreaks of multidrug-
resistant bacteria are increasingly reported.37-40
This is despite the enhanced resourcing of infection
prevention and control teams and greater emphasis
on antimicrobial stewardship, albeit sometimes ret-
rospectively. As healthcare costs constitute signiﬁ-
cant percentages of national budgets, and capital
investments in physical infrastructure and staff
recruitment attempt to cope with aging populations
and higher levels of patient throughput than was
previously anticipated, there are opportunities for
the deploying of new technologies to delay or halt
generation of antimicrobial resistance.
Initiatives such as One Health are important at
national and international scale. However, within
individual healthcare systems or local healthcare
facilities, there will be opportunities to instigate
changes that will be impactful. These will relate to
the integration of medical, management and
hygiene staff into teams that understand and deal
collectively with infection prevention and control
and with outbreaks or affected patients, both from
clinical and human perspectives; there will also be
decisions made regarding the appropriateness of
adoption or otherwise of new technologies, such as
antimicrobial coatings.
AMiCI aims to aid these decisions through provi-
sion of credible information that recognizes the some-
times aligned, but sometimes disparate, perspectives
of stakeholders and target groups.
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